Charles River Laboratories International (CRL) – Investment Analysts’ Recent Ratings Updates

Charles River Laboratories International (NYSE: CRL) has recently received a number of price target changes and ratings updates:

• 7/20/2026 – Charles River Laboratories International was downgraded by CLSA from “outperform” to “hold”. They now have a $219.00 price target on the stock.
• 7/13/2026 – Charles River Laboratories International had its price target raised by Mizuho from $192.00 to $230.00. They now have a “neutral” rating on the stock.
• 7/9/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $220.00 to $260.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Charles River Laboratories International had its “buy” rating reaffirmed by Citigroup Inc..
• 7/1/2026 – Charles River Laboratories International was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by Sanford C. Bernstein.
• 7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by BNP Paribas Exane.
• 6/17/2026 – Charles River Laboratories International was upgraded by Morgan Stanley from “equal weight” to “overweight”. They now have a $220.00 price target on the stock, up from $185.00.
• 6/16/2026 – Charles River Laboratories International was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/29/2026 – Charles River Laboratories International was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/29/2026 – Charles River Laboratories International was upgraded by CLSA from “hold” to “outperform”. They now have a $219.00 price target on the stock, up from $167.00.

Insider Activity at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.